Actovegin®

Contents: 1 tablet coated film contains:

Kernel: active substance: blood components: deproteinized hemodereal blood of calves - 200 mg, excipients: magnesium stearate, povidone (K 90), talc, cellulose.

Shell: acacia gum, mountain glycolic wax, hypromellose phthalate, diethyl phthalate, dye quinoline yellow aluminum lacquer, macrogol (6000), povidone (K 30), sucrose, talc, titanium dioxide.

Description: greenish-yellow shiny round coated tablets.

Pharmacotherapeutic group: Regeneration of tissue stimulant.Код ATX: [B06AB]

Pharmacodynamics

Antihypoxant. ACTOVEGIN® is a hemoderivat, which is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5,000 daltons pass through). It has a positive effect on transport and utilization of glucose, stimulates oxygen consumption (which leads to stabilization of plasma cell membranes in ischemia and reduced lactate formation), thus having an antihypoxic effect that begins to appear at the latest 30 minutes after oral administration and reaches a maximum on average after 3 hours (2-6 hours).

ACTOVEGIN ® increases the concentrations of adenosine triphosphate, adenosine diphosphate, phosphocreatine, as well as amino acids - glutamate, aspartate and gamma-aminobutyric acid.

The effect of ACTOVEGIN® on the assimilation and utilization of oxygen, as well as insulin-like activity with the stimulation of transport and glucose oxidation, are significant in the treatment of diabetic polyneuropathy (DPN).

In patients with diabetes mellitus and diabetic polyneuropathy, ACTOVEGIN® reliably reduces symptoms of polyneuropathy (stitching, burning sensation, paresthesia, numbness in the lower limbs). Objective disorders are reduced sensitivity, mental well-being of patients improves.

Pharmacokinetics

With the help of pharmacokinetic methods it is impossible to study the pharmacokinetic indices of the drug ACTOVEGIN®, since it consists only of the physiological components that are usually present in the body.

To date, there has been no reduction in the pharmacological effect of hemoderovatives in patients with altered pharmacokinetics (eg, hepatic or renal insufficiency, metabolic changes associated with advanced age, and metabolic peculiarities in newborns).

Indications

• Complex therapy of metabolic and cerebral disorders of the brain (various forms of cerebral circulatory insufficiency, dementia, craniocerebral trauma);

• Peripheral (arterial and venous) vascular disorders and their consequences (angiopathy, trophic ulcers); diabetic polyneuropathy.

Contraindications

- Hypersensitivity to the drug Actovegin® or similar drugs.

- Fructose intolerance, Glucose galactose malabsorption,

- Age under 18.

Carefully:

Heart failure of II and III degree, pulmonary edema, oliguria, anuria, hyperhydration; pregnancy, lactation.
The use of Actovegin Pills in pregnancy is allowed if the benefit exceeds the potential risk to the fetus, and strictly upon doctor's indications.

Dosing and Administration

Orally, 1-2 tablets 3 times a day, without chewing, before eating, squeezed a small amount of liquid. Duration of treatment should be from 4 to 6 weeks.

With diabetic polyneuropathy: 2000 mg per day intravenously for 3 weeks with the subsequent transition to the tablet form - 2-3 tablets 3 times a day for at least 4-5 months.

Side effects

Immune system complications

Rare: Allergic reaction (drug-induced fever, symptoms of shock).

Skin and subcutaneous complications

Rare: Hives, sudden redness.

In such cases, treatment with Actovegin® should be discontinued. If necessary, a standard therapy for allergic reactions (antihistamines and / or corticosteroids) is performed.

Interaction with other drugs: Currently unknown.

Form of issue
The coated tablets 200 mg.

For 50 tablets in bottles of dark glass (type III, Eur.pharm.) With a screw neck and a screw cap providing control of the first opening. 1 bottle with the instruction for use is placed in a cardboard box. On the pack are glued transparent protective labels of a round shape with holographic inscriptions and the control of the first autopsy.

In the case of packaging and packaging of the drug on ZAO "FarmFirma Soteks":

For 10, 30, or 50 tablets in bottles of brown glass, corked with aluminum caps with the control of the first opening. 1 bottle with instruction for use is placed in a pack of cardboard.

Shelf life
3 years. Do not use after expiry date.

Storage conditions
At a temperature of no higher than 25 ° C in a dark place.

Keep out of the reach of children!

Country of manufacture:

Austria, Russia